Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 06:10:36 2024-05-14 am EDT			5-day change	1st Jan Change
156 ^EUR	+0.95%		+1.82%	+8.47%

May. 13	Cinven to explore $3 billion sale of software maker Jaggaer, sources say	RE
May. 08	MERCK KGAA : UBS reiterates its Buy rating	ZD

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

November 10, 2022 at 08:00 am EST

MERCK Kommanditgesellschaft auf Aktien provided earnings guidance for the full year 2022. For the period, the company expects net sales to be in a range of EUR 22 billion to EUR 22.9 billion and EPS pre to be in a range of EUR 9.9 to EUR 10.7.

Latest news about Merck KGaA

Cinven to explore $3 billion sale of software maker Jaggaer, sources say	May. 13	RE
MERCK KGAA : UBS reiterates its Buy rating	May. 08	ZD
MERCK KGAA : Gets a Buy rating from JP Morgan	May. 07	ZD
MERCK KGAA : Receives a Buy rating from Deutsche Bank	May. 07	ZD
Biocartis, Merck KGaA Expand Cancer Biomarker Testing Collaboration into MENA Region	May. 06	MT
MERCK KGAA : Gets a Buy rating from UBS	May. 06	ZD
Biocartis Announces Expansion of Its Collaboration with Merck Serono Middle East and North Africa	May. 06	CI
MERCK KGAA : JP Morgan maintains a Buy rating	May. 03	ZD
MERCK KGAA : Jefferies keeps its Buy rating	May. 01	ZD
Habeck's 'pharma trip' - industry sees structural problems	Apr. 29	DP
Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board	Apr. 26	DP
Transcript : Merck KGaA - Shareholder/Analyst Call	Apr. 26
Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Merck KGaA Starts Building EUR300 Million Life Science Research Center in Germany	Apr. 25	MT
Scholz visits Merck and Family Business Days	Apr. 24	DP
US competitor Danaher boosts Merck KGaA and Sartorius	Apr. 23	DP
MERCK KGAA : Barclays reiterates its Buy rating	Apr. 19	ZD
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Agronomics Portfolio Company Mosa Meat Raises EUR40 Million to Beef Up Production	Apr. 17	MT
Merck KGaA Rolls Out New Genetic Stability Assay Platform	Apr. 16	MT
MERCK : A peer group tidy up	Apr. 13
Merck Announces Change of Managing Director of Merck Life Science in India	Apr. 09	CI
Caris Life Sciences Announces Partnership with Merck KGaA to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	Apr. 04	CI
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI

Chart Merck KGaA

Duration

Period

More charts

Company Profile

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A peer group tidy up

April 13, 2024 at 04:06 pm EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154.5 EUR

Average target price

179.8 EUR

Spread / Average Target

+16.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+8.47%	72.5B
KYOWA KIRIN CO. LTD.	+13.69%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-11.75%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+59.61%	5.01B
YUHAN CORPORATION	+2.62%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-17.54%	2.46B
INDIVIOR PLC	+21.27%	2.44B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.82%	2.26B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+25.13%	2.27B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

EPS Revisions